These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 16118342

  • 21. Substitution of valine-865 by methionine or leucine in the human androgen receptor causes complete or partial androgen insensitivity, respectively with distinct androgen receptor phenotypes.
    Kazemi-Esfarjani P, Beitel LK, Trifiro M, Kaufman M, Rennie P, Sheppard P, Matusik R, Pinsky L.
    Mol Endocrinol; 1993 Jan; 7(1):37-46. PubMed ID: 8446106
    [Abstract] [Full Text] [Related]

  • 22. A novel mutation F826L in the human androgen receptor in partial androgen insensitivity syndrome; increased NH2-/COOH-terminal domain interaction and TIF2 co-activation.
    Wong HY, Hoogerbrugge JW, Pang KL, van Leeuwen M, van Royen ME, Molier M, Berrevoets CA, Dooijes D, Dubbink HJ, van de Wijngaart DJ, Wolffenbuttel KP, Trapman J, Kleijer WJ, Drop SL, Grootegoed JA, Brinkmann AO.
    Mol Cell Endocrinol; 2008 Sep 24; 292(1-2):69-78. PubMed ID: 18656523
    [Abstract] [Full Text] [Related]

  • 23. Bridging structural biology and genetics by computational methods: an investigation into how the R774C mutation in the AR gene can result in complete androgen insensitivity syndrome.
    Wu JH, Gottlieb B, Batist G, Sulea T, Purisima EO, Beitel LK, Trifiro M.
    Hum Mutat; 2003 Dec 24; 22(6):465-75. PubMed ID: 14635106
    [Abstract] [Full Text] [Related]

  • 24. A new mutation of the androgen receptor, P817A, causing partial androgen insensitivity syndrome: in vitro and structural analysis.
    Lumbroso S, Wagschal A, Bourguet W, Georget V, Mazen I, Servant N, Audran F, Sultan C, Auzou G.
    J Mol Endocrinol; 2004 Jun 24; 32(3):679-87. PubMed ID: 15171708
    [Abstract] [Full Text] [Related]

  • 25. Evidence that lack of ligand-binding domain correlates with nuclear distribution of unliganded human androgen receptor and loss of transactivation activity.
    Suzuki N, Imai A.
    Gynecol Endocrinol; 2011 Nov 24; 27(11):940-3. PubMed ID: 21501000
    [Abstract] [Full Text] [Related]

  • 26. Functional analysis of a novel androgen receptor mutation, Q902K, in an individual with partial androgen insensitivity.
    Umar A, Berrevoets CA, Van NM, van Leeuwen M, Verbiest M, Kleijer WJ, Dooijes D, Grootegoed JA, Drop SL, Brinkmann AO.
    J Clin Endocrinol Metab; 2005 Jan 24; 90(1):507-15. PubMed ID: 15486055
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome.
    Ahmed SF, Cheng A, Dovey L, Hawkins JR, Martin H, Rowland J, Shimura N, Tait AD, Hughes IA.
    J Clin Endocrinol Metab; 2000 Feb 24; 85(2):658-65. PubMed ID: 10690872
    [Abstract] [Full Text] [Related]

  • 30. Single base mutations in the human androgen receptor gene causing complete androgen insensitivity: rapid detection by a modified denaturing gradient gel electrophoresis technique.
    De Bellis A, Quigley CA, Cariello NF, el-Awady MK, Sar M, Lane MV, Wilson EM, French FS.
    Mol Endocrinol; 1992 Nov 24; 6(11):1909-20. PubMed ID: 1480178
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Mutations in the amino-terminal domain of the human androgen receptor may be associated with partial androgen insensitivity and impaired transactivation in vitro.
    Holterhus PM, Werner R, Struve D, Hauffa BP, Schroeder C, Hiort O.
    Exp Clin Endocrinol Diabetes; 2005 Sep 24; 113(8):457-63. PubMed ID: 16151980
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines.
    Nakauchi H, Matsuda K, Ochiai I, Kawauchi A, Mizutani Y, Miki T, Kawata M.
    J Histochem Cytochem; 2007 Jun 24; 55(6):535-44. PubMed ID: 17312014
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Transcription activating and repressing functions of the androgen receptor are differentially influenced by mutations in the deoxyribonucleic acid-binding domain.
    Aarnisalo P, Santti H, Poukka H, Palvimo JJ, Jänne OA.
    Endocrinology; 1999 Jul 24; 140(7):3097-105. PubMed ID: 10385402
    [Abstract] [Full Text] [Related]

  • 38. C601S mutation in the androgen receptor results in partial loss of androgen function.
    Singh R, Singh P, Gupta NJ, Chakrabarty B, Singh L, Thangaraj K.
    J Steroid Biochem Mol Biol; 2010 Nov 24; 122(5):359-63. PubMed ID: 20493947
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.